Drug
Xyrem
Xyrem: highest development phase Phase 3, developed by Jazz Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Xyrem® NCT00371137 | Phase 3 | Fibromyalgia |
| Xyrem (sodium oxybate) oral solution NCT00087555 | Phase 2 | Fibromyalgia |
Latest
No recent events.
Follow Xyrem on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.